Pioglitazone antidiabetic drugs
systematic review meta-analysis network meta-analysis
 

Actos      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathmyocardial infarction (fatal and non fatal)

diabetes type 2  

EC404   pioglitazonemetforminExploratory negative50%-25%
EC409   pioglitazone + sulfonylureametformin + sulfonylureaExploratory negative-25%-20%
PROactive, 2005      NCTpioglitazoneplaceboLow risk of bias suggesting -4%-18%
PNFP-026   pioglitazoneplaceboExploratory negative-100%
PNFP-012   pioglitazoneplaceboExploratory negative-100%-100%
PNFP-001   pioglitazoneplaceboExploratory negative-76%
PROACTIVE      NCTpioglitazoneplacebo -
IRIS, 2016      NCTpioglitazoneplacebo -
PNFP-014   pioglitazone + insulinplacebo (add on insulin)Exploratory negative∞%
OPI-502   pioglitazone + insulinplacebo (add on insulin)Exploratory negative-100%
PNFP-027   pioglitazone + metforminplacebo (add on MET)Exploratory negative
GLAI    NCTpioglitazonerosiglitazoneExploratory negative-50%-50%
OPI-504    NCTpioglitazonesulfonylureaExploratory negative 59%144%
EC405   pioglitazonesulfonylureaExploratory negative-20%0%
OPI-501   pioglitazonesulfonylureaExploratory negative-100%0%
OPI-520    NCTpioglitazonesulfonylureaExploratory negative0%-1%
OPI-506    NCTpioglitazonesulfonylureaExploratory negative-83%-42%
PNFP-010   pioglitazone + sulfonylureasulfonylureaExploratory negative-75%-50%
EC410   pioglitazone + metforminsulfonylurea + metforminExploratory negative0%394%
Bolli, 2008       pioglitazonevildagliptinnegative
PERISCOPE, 2008      NCTpioglitazoneglimepirideLow risk of bias negative-50%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons